Protagonist Therapeutics (PTGX) Jefferies Global Healthcare Conference 2026 summary

Commercial and financial highlights

• Significant royalty streams from partnerships, notably with J&J for ICOTYDE and Takeda for rusfertide, support a strong financial position and self-funded R&D through clinical proof of concept.

• ICOTYDE, approved for psoriasis and in phase III for additional indications, is projected by J&J to become its largest drug, with early prescription numbers exceeding third-party database reports.

• Royalty revenue from ICOTYDE will be reported as a separate line, with recognition lagging J&J's reporting by 1–2 months.

• Rusfertide is under priority review with a Q3 PDUFA date; opting out of co-commercialization with Takeda secures up to $425 million in payments and a 14–29% royalty on net sales.

• Share buyback programs are under consideration, with potential announcements by year-end if rusfertide is approved.

Pipeline and R&D strategy

• Proprietary peptide platform underpins a robust pipeline, with a focus on validated biological targets to reduce risk.

• Oral IL-17 program leverages learnings from antibody drugs, with phase I data in Q3 guiding a go/no-go decision for phase II in psoriasis and potential rapid expansion to other indications.

• Obesity franchise centers on differentiated oral and subQ triple G agonists, designed with KOL input to maximize efficacy and minimize side effects, with multiple assets in development.

• Financial strength allows simultaneous pursuit of multiple programs without prioritization or need for near-term fundraising.

• R&D and G&A spending are fully supported by existing resources, with a strategy to fund programs through clinical proof of concept.

Industry positioning and outlook

• Partnerships with major pharma companies provide validation and de-risking, with J&J and Takeda both highly engaged in their respective programs.

• ICOTYDE's safety profile, including no TB screening requirement, and potential for oral delivery position it as a market-expanding product.

• Market research suggests a significant patient shift from injectables to oral therapies if effective options are available.

• The company is viewed as undervalued relative to the long-term revenue potential of its partnered products.

• Plans for share buybacks and perennial capital return are contingent on continued commercial success.